CN106176593A - A kind of eye drip Rimactane and preparation method thereof - Google Patents
A kind of eye drip Rimactane and preparation method thereof Download PDFInfo
- Publication number
- CN106176593A CN106176593A CN201610744871.3A CN201610744871A CN106176593A CN 106176593 A CN106176593 A CN 106176593A CN 201610744871 A CN201610744871 A CN 201610744871A CN 106176593 A CN106176593 A CN 106176593A
- Authority
- CN
- China
- Prior art keywords
- gram
- rimactane
- reagent
- grams
- eye drip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title claims abstract description 33
- 229940049560 rimactane Drugs 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 16
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 16
- 229960001225 rifampicin Drugs 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 13
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 13
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 13
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004327 boric acid Substances 0.000 claims abstract description 11
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000008215 water for injection Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 229960003080 taurine Drugs 0.000 claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 50
- 230000001954 sterilising effect Effects 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 16
- 238000004659 sterilization and disinfection Methods 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000005864 Sulphur Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 208000022873 Ocular disease Diseases 0.000 abstract description 3
- 230000001741 anti-phlogistic effect Effects 0.000 abstract description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 210000001508 eye Anatomy 0.000 description 18
- 239000003814 drug Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of eye drip Rimactane; its raw material is as follows: rifampicin 8 10 grams; 0.3 0.5 grams of sodium chloride; Borneolum Syntheticum 23 grams, sodium dihydrogen phosphate 1 1.5 grams, disodium hydrogen phosphate 1 1.3 grams; boric acid 0.5 0.8 grams; disodiumedetate 0.6 0.8 grams, taurine 0.1 0.2 grams, water for injection 80 100 milliliters.A kind of eye drip Rimactane that the present invention provides and preparation method thereof, make collyrium can obtain the effect of good fatigue alleviating by the mixing of Multiple components, there is higher bactericidal antiphlogistic effect simultaneously, effectively the pathogenic bacteria infected can be eliminated, ocular disease is effectively eliminated.
Description
Technical field
The present invention relates to eye drop technical field, particularly relate to a kind of eye drip Rimactane and preparation method thereof.
Background technology
Collyrium is the liquid medicine for the treatment of disease of eye, and its composition has numerous species according to the difference of effect, such as steroid, anti-
Raw element, antihistaminic, beta-blocker, non-steroidal anti-inflammatory analgesic etc..General collyrium with the addition of to preserve for a long time
The preservative of trace, will not impact human body under normal use.If but life-time service contains the collyrium of preservative, relatively
Easily cause cornea injured, the symptoms such as one's eyes became bloodshot, photophobia occur.Different collyrium has respective purposes, such as, treat eye
Eyeball infection, reduction intraocular pressure, anti-inflammatory analgetic or eyes of releiving are dry and astringent.Such as other drug, many collyrium all have some degree
Side effect.Rifampicin is semi-synthetic wide-spectrum bactericide, with the β subunit strong bonded of the RNA polymerase depending on DNA, suppression
The synthesis of bacteria RNA, prevents this enzyme to be connected with DNA, thus blocks rna transcription process.Rifampicin has well for collyrium
Effect, eye can well be eliminated, have good bactericidal effect.
Summary of the invention
The invention aims to solve shortcoming present in prior art, and a kind of eye drip rifampicin system proposed
Agent and preparation method thereof.
To achieve these goals, present invention employs following technical scheme:
A kind of eye drip Rimactane, its raw material is as follows: rifampicin 8-10 gram, 0.3-0.5 gram of sodium chloride, Borneolum Syntheticum
2-3 gram, sodium dihydrogen phosphate 1-1.5 gram, disodium hydrogen phosphate 1-1.3 gram, boric acid 0.5-0.8 gram, disodiumedetate 0.6-
0.8 gram, taurine 0.1-0.2 gram, water for injection 80-100 milliliter.
Preferably, described Borneolum Syntheticum is the powder after grinding, and powder mesh number is 800 mesh.
Preferably, described disodium hydrogen phosphate and sodium dihydrogen phosphate are anhydrous state.
The preparation method of a kind of eye drip Rimactane, comprises the steps:
The preparation of S1: reagent bottle, carries out sterilization treatment by reagent bottle at high-temperature steam cabinet, and being then dried process can make
With；
S2: by rifampicin, sodium chloride, Borneolum Syntheticum, sodium dihydrogen phosphate, disodium hydrogen phosphate, boric acid, disodiumedetate, cattle sulphur
Acid and water for injection join and carry out in reagent bottle dissolving mixing, it is thus achieved that mix reagent, use water-bath during dissolving mixing
The mode of heating, bath temperature controls between 50-60 degree Celsius；
S3: fine straining processes, and the mix reagent obtained in S2 is carried out in defecator filtration treatment, and the mesh number of drainage screen is
800 mesh, need mix reagent is rocked vibrations, it is to avoid some precipitations caused in fine straining processing procedure simultaneously
Filter is not exclusively；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing
Reason, sterilization time is at least 30 minutes；
S5: Detection, detects the mix reagent via high-temp steam sterilizing, examines after taking out reagent on detection equipment
Survey, thus learn whether sterilizing reaches standard；
S6: sub-bottle packaging, is vacuum-packed in the vial by detecting qualified mix reagent through S5.
A kind of eye drip Rimactane that the present invention provides and preparation method thereof, makes eye by the mixing of Multiple components
Liquid medicine can obtain the effect of good fatigue alleviating, has higher bactericidal antiphlogistic effect simultaneously, can be effectively by infection
Pathogenic bacteria eliminates, and is effectively eliminated by ocular disease.
Detailed description of the invention
In order to make the purpose of the present invention, technical scheme and advantage clearer, below in conjunction with specific embodiment, to this
Invention is further elaborated.Should be appreciated that specific embodiment described herein only in order to explain the present invention, not
For limiting the present invention.
Embodiment 1
A kind of eye drip Rimactane, its raw material is as follows: rifampicin 8 grams, 0.3 gram of sodium chloride, Borneolum Syntheticum 2 grams, phosphorus
1 gram of acid dihydride sodium, disodium hydrogen phosphate 1 gram, boric acid 0.5 gram, disodiumedetate 0.6 gram, taurine 0.1 gram, injection
80 milliliters of water.
Described Borneolum Syntheticum is the powder after grinding, and powder mesh number is 800 mesh.
Described disodium hydrogen phosphate and sodium dihydrogen phosphate are anhydrous state.
The preparation method of a kind of eye drip Rimactane, comprises the steps:
The preparation of S1: reagent bottle, carries out sterilization treatment by reagent bottle at high-temperature steam cabinet, and being then dried process can make
With；
S2: by rifampicin, sodium chloride, Borneolum Syntheticum, sodium dihydrogen phosphate, disodium hydrogen phosphate, boric acid, disodiumedetate, cattle sulphur
Acid and water for injection join and carry out in reagent bottle dissolving mixing, it is thus achieved that mix reagent, use water-bath during dissolving mixing
The mode of heating, bath temperature controls between 50-60 degree Celsius；
S3: fine straining processes, and the mix reagent obtained in S2 is carried out in defecator filtration treatment, and the mesh number of drainage screen is
800 mesh, need mix reagent is rocked vibrations, it is to avoid some precipitations caused in fine straining processing procedure simultaneously
Filter is not exclusively；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing
Reason, sterilization time is at least 30 minutes；
S5: Detection, detects the mix reagent via high-temp steam sterilizing, examines after taking out reagent on detection equipment
Survey, thus learn whether sterilizing reaches standard；
S6: sub-bottle packaging, is vacuum-packed in the vial by detecting qualified mix reagent through S5.
Embodiment 2
A kind of eye drip Rimactane, its raw material is as follows: rifampicin 9 grams, 0.4 gram of sodium chloride, Borneolum Syntheticum 2.5 grams,
Sodium dihydrogen phosphate 1.25 grams, disodium hydrogen phosphate 1.15 grams, boric acid 0.7 gram, disodiumedetate 0.7 gram, taurine 0.15
Gram, water for injection 90 milliliters.
Described Borneolum Syntheticum is the powder after grinding, and powder mesh number is 800 mesh.
Described disodium hydrogen phosphate and sodium dihydrogen phosphate are anhydrous state.
The preparation method of a kind of eye drip Rimactane, comprises the steps:
The preparation of S1: reagent bottle, carries out sterilization treatment by reagent bottle at high-temperature steam cabinet, and being then dried process can make
With；
S2: by rifampicin, sodium chloride, Borneolum Syntheticum, sodium dihydrogen phosphate, disodium hydrogen phosphate, boric acid, disodiumedetate, cattle sulphur
Acid and water for injection join and carry out in reagent bottle dissolving mixing, it is thus achieved that mix reagent, use water-bath during dissolving mixing
The mode of heating, bath temperature controls between 50-60 degree Celsius；
S3: fine straining processes, and the mix reagent obtained in S2 is carried out in defecator filtration treatment, and the mesh number of drainage screen is
800 mesh, need mix reagent is rocked vibrations, it is to avoid some precipitations caused in fine straining processing procedure simultaneously
Filter is not exclusively；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing
Reason, sterilization time is at least 30 minutes；
S5: Detection, detects the mix reagent via high-temp steam sterilizing, examines after taking out reagent on detection equipment
Survey, thus learn whether sterilizing reaches standard；
S6: sub-bottle packaging, is vacuum-packed in the vial by detecting qualified mix reagent through S5.
Embodiment 3
A kind of eye drip Rimactane, its raw material is as follows: rifampicin 10 grams, 0.5 gram of sodium chloride, Borneolum Syntheticum 3 grams, phosphorus
1.5 grams of acid dihydride sodium, disodium hydrogen phosphate 1.3 grams, boric acid 0.8 gram, disodiumedetate 0.8 gram, taurine 0.2 gram, note
Penetrate with 100 milliliters of water.
Described Borneolum Syntheticum is the powder after grinding, and powder mesh number is 800 mesh.
Described disodium hydrogen phosphate and sodium dihydrogen phosphate are anhydrous state.
The preparation method of a kind of eye drip Rimactane, comprises the steps:
The preparation of S1: reagent bottle, carries out sterilization treatment by reagent bottle at high-temperature steam cabinet, and being then dried process can make
With；
S2: by rifampicin, sodium chloride, Borneolum Syntheticum, sodium dihydrogen phosphate, disodium hydrogen phosphate, boric acid, disodiumedetate, cattle sulphur
Acid and water for injection join and carry out in reagent bottle dissolving mixing, it is thus achieved that mix reagent, use water-bath during dissolving mixing
The mode of heating, bath temperature controls between 50-60 degree Celsius；
S3: fine straining processes, and the mix reagent obtained in S2 is carried out in defecator filtration treatment, and the mesh number of drainage screen is
800 mesh, need mix reagent is rocked vibrations, it is to avoid some precipitations caused in fine straining processing procedure simultaneously
Filter is not exclusively；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing
Reason, sterilization time is at least 30 minutes；
S5: Detection, detects the mix reagent via high-temp steam sterilizing, examines after taking out reagent on detection equipment
Survey, thus learn whether sterilizing reaches standard；
S6: sub-bottle packaging, is vacuum-packed in the vial by detecting qualified mix reagent through S5.
A kind of eye drip Rimactane that the present invention provides and preparation method thereof, makes eye by the mixing of Multiple components
Liquid medicine can obtain the effect of good fatigue alleviating, has higher bactericidal antiphlogistic effect simultaneously, can be effectively by infection
Pathogenic bacteria eliminates, and is effectively eliminated by ocular disease.
The above, the only present invention preferably detailed description of the invention, but protection scope of the present invention is not limited thereto,
Any those familiar with the art in the technical scope that the invention discloses, according to technical scheme and
Inventive concept equivalent or change in addition, all should contain within protection scope of the present invention.
Claims (4)
1. an eye drip Rimactane, it is characterised in that: its raw material is as follows: rifampicin 8-10 gram, sodium chloride
0.3-0.5 gram, Borneolum Syntheticum 2-3 gram, sodium dihydrogen phosphate 1-1.5 gram, disodium hydrogen phosphate 1-1.3 gram, boric acid 0.5-0.8 gram, ethylenediamine
Tetraacethyl disodium 0.6-0.8 gram, taurine 0.1-0.2 gram, water for injection 80-100 milliliter.
A kind of eye drip Rimactane the most according to claim 1, it is characterised in that: described Borneolum Syntheticum is after grinding
Powder, and powder mesh number is 800 mesh.
A kind of eye drip Rimactane the most according to claim 1, it is characterised in that: described disodium hydrogen phosphate and phosphoric acid
Sodium dihydrogen is anhydrous state.
4. the preparation method of the eye drip Rimactane described in a claim 1, it is characterised in that: comprise the steps:
The preparation of S1: reagent bottle, carries out sterilization treatment by reagent bottle at high-temperature steam cabinet, and being then dried process can make
With；
S2: by rifampicin, sodium chloride, Borneolum Syntheticum, sodium dihydrogen phosphate, disodium hydrogen phosphate, boric acid, disodiumedetate, cattle sulphur
Acid and water for injection join and carry out in reagent bottle dissolving mixing, it is thus achieved that mix reagent, use water-bath during dissolving mixing
The mode of heating, bath temperature controls between 50-60 degree Celsius；
S3: fine straining processes, and the mix reagent obtained in S2 is carried out in defecator filtration treatment, and the mesh number of drainage screen is
800 mesh, need mix reagent is rocked vibrations, it is to avoid some precipitations caused in fine straining processing procedure simultaneously
Filter is not exclusively；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing
Reason, sterilization time is at least 30 minutes；
S5: Detection, detects the mix reagent via high-temp steam sterilizing, examines after taking out reagent on detection equipment
Survey, thus learn whether sterilizing reaches standard；
S6: sub-bottle packaging, is vacuum-packed in the vial by detecting qualified mix reagent through S5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610744871.3A CN106176593A (en) | 2016-08-29 | 2016-08-29 | A kind of eye drip Rimactane and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610744871.3A CN106176593A (en) | 2016-08-29 | 2016-08-29 | A kind of eye drip Rimactane and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176593A true CN106176593A (en) | 2016-12-07 |
Family
ID=57526968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610744871.3A Pending CN106176593A (en) | 2016-08-29 | 2016-08-29 | A kind of eye drip Rimactane and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176593A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108690313A (en) * | 2017-04-07 | 2018-10-23 | 健管（厦门）环境科技有限公司 | A kind of tube inner linking material for pipeline local repair and its manufacturing method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1185953A (en) * | 1996-12-27 | 1998-07-01 | 刘伟中 | Eye drop containing rich oxygen and preparation thereof |
| CN1629679A (en) * | 2003-12-16 | 2005-06-22 | 上海卫康光学有限公司 | Ophthalmic solution containing borneol and usage thereof |
| CN103394077A (en) * | 2010-06-25 | 2013-11-20 | 杨红宇 | Eye drop |
| WO2016014437A1 (en) * | 2014-07-21 | 2016-01-28 | Hiroaki Serizawa | Ophthalmic compositions of rifamycins and uses thereof |
-
2016
- 2016-08-29 CN CN201610744871.3A patent/CN106176593A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1185953A (en) * | 1996-12-27 | 1998-07-01 | 刘伟中 | Eye drop containing rich oxygen and preparation thereof |
| CN1629679A (en) * | 2003-12-16 | 2005-06-22 | 上海卫康光学有限公司 | Ophthalmic solution containing borneol and usage thereof |
| CN103394077A (en) * | 2010-06-25 | 2013-11-20 | 杨红宇 | Eye drop |
| WO2016014437A1 (en) * | 2014-07-21 | 2016-01-28 | Hiroaki Serizawa | Ophthalmic compositions of rifamycins and uses thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108690313A (en) * | 2017-04-07 | 2018-10-23 | 健管（厦门）环境科技有限公司 | A kind of tube inner linking material for pipeline local repair and its manufacturing method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Autologous platelet-rich plasma eye drops in the treatment of recurrent corneal erosions | |
| CN102170865A (en) | Eye drop with difluprednate for macular edema treatment | |
| CN101716214A (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| TW200911277A (en) | An agent for preventing or decreasing peripheral neuropathy by an anticancer drug | |
| AU2014343506C1 (en) | Anti-inflammatory solution comprising sodium hypochlorite | |
| CN106176593A (en) | A kind of eye drip Rimactane and preparation method thereof | |
| Check et al. | Check. Various Presentations of The Increased Cellular Permeability Syndrome in Males Responding Very Well to Sympathomimetic Amine Therapy–Possible Treatment for End-Stage Covid-19 Complications | |
| CN103393693B (en) | Pharmaceutical composition of ondansetron hydrochloride and dexamethasone | |
| Halasa et al. | Thymoxamine therapy for angle-closure glaucoma | |
| CN106822284A (en) | A kind of medicine for treating irregular menstruation | |
| CN106389427B (en) | Pharmaceutical composition and drug and application containing Temozolomide | |
| CN105213323A (en) | A kind of preparation method of injection vinpocetine lyophilized powder | |
| Olcaysu et al. | Unilateral Optic Neuropathy and Acute Angle‐Closure Glaucoma following Snake Envenomation | |
| CN103550357B (en) | A kind of control muscae volitantes collyrium and its production and use | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN109464458A (en) | A kind of peritoneal dialysis solution (lactate) composition and preparation method thereof | |
| CN102727425A (en) | Nitroimidazole oculentum and preparation method thereof | |
| CN104523579B (en) | The preparation method of armillarisin A glucose injection | |
| CN108175797B (en) | A topical Chinese medicinal preparation for treating ocular surface diseases, and its preparation method | |
| CN106214627A (en) | The preparation method of Betahistine Hydrochloride sodium chloride injection | |
| CN105362274A (en) | Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals | |
| CN208525227U (en) | A kind of hospital gauze | |
| Dong et al. | Fibrin glue-assisted for the treatment of corneal perforations using glycerin-cryopreserved corneal tissue | |
| CN105106383B (en) | External traditional Chinese medicine for treating tourette syndrome | |
| CN105748512A (en) | Specific medicine for empyrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161207 |